Why K2 and D3 Are Sold Together

Vitamin D3 and vitamin K2 are sold together often enough that the pairing looks like marketing convenience. It is not. There is a specific biochemical reason they belong in the same capsule, and it is worth understanding — including the part where the evidence gets less certain than the label suggests.

The pairing, in one sentence

D3 increases how much calcium you absorb. K2 is involved in directing where that calcium ends up.

What D3 does

Vitamin D3 raises intestinal calcium absorption. That is its central, uncontroversial role, and it is why D3 sits in bone-health formulas.

Absorbing more calcium is only useful if the calcium is deposited where you want it. Bone is the intended destination. Arterial wall is not.

What K2 does

Vitamin K acts as a cofactor for the enzyme gamma-glutamyl carboxylase. That enzyme carboxylates a family of vitamin K-dependent proteins, converting specific glutamate residues into gamma-carboxyglutamic acid and switching the proteins into their active form.

Two of those proteins matter here. Osteocalcin is involved in binding calcium into bone. Matrix Gla protein, or MGP, is a potent inhibitor of vascular calcification.

Without enough vitamin K, MGP stays uncarboxylated and inactive. Low vitamin K status and high circulating uncarboxylated MGP have repeatedly been associated with accelerated vascular calcification.

There is a further wrinkle that makes the pairing tighter: vitamin D appears to stimulate production of some of these same vitamin K-dependent proteins. Producing more of a protein that needs vitamin K to be activated, without supplying the vitamin K, is not obviously useful.

The trial people cite

The study that anchors most K2 marketing is Knapen and colleagues, published in Thrombosis and Haemostasis in 2015.

It was a double-blind randomised trial of 244 healthy postmenopausal women, given either 180 micrograms a day of MK-7 or placebo, for three years. Three years is an unusually long run for a supplement trial.

After three years, carotid-femoral pulse wave velocity and the Stiffness Index beta both decreased significantly in the MK-7 group. The effect was largest in women who started with the stiffest arteries. Inactive MGP fell by about half against placebo.

That is a real result from a well-designed trial, and it is the strongest single piece of evidence for the pairing.

Where the evidence stops

It is also one trial, in one population, at one dose, of one form of vitamin K.

A 2020 systematic review in Nutrients by Vlasschaert and colleagues looked at nine randomised controlled trials of vitamin K1 or K2 against surrogate measures of cardiovascular disease — arterial calcification, atherosclerosis, arterial stiffening. Its conclusion was that vitamin K does not consistently prevent the progression of any of them.

Broader reviews reach similar places. High-quality trials of combined vitamin D and K supplementation specifically are limited, and cardiovascular outcome data are largely observational and inconsistent.

So the mechanism is well established. The clinical payoff is not settled. Anyone presenting K2 as proven cardiovascular protection is reading past the reviews.

How we pair them

Our K2 + D3 combines vitamin D3, vitamin K2 as MK-7, and calcium, with BioPerine for absorption. One capsule twice daily.

Take it with a meal that contains some fat. Both D3 and K2 are fat-soluble, and that single detail changes how much you actually absorb more than most of the choices on the label do.

One caution worth stating plainly: if you take a vitamin K antagonist such as warfarin, vitamin K supplements interact with your medication directly. Talk to whoever manages your prescription before starting one.